1-20 of 43
Alan D. D’Andrea
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5725: The USP1 inhibitor I-138 kills BRCA1-deficient tumor cells and overcomes PARP inhibitor resistance

Alexandre Andre B. A. Da Costa, Arindam Bose, David Martignetti, Cecilia Ayala-Zambrano, Ramya Ravindranathan, Golbahar Sadatrezaei, Yuqing Jiao, Bose Kochupurakkal, Huy Nguyen, Jean-Bernard Lazaro, Kalindi Parmar, Geoffrey I. Shapiro, Alan D. D’Andrea
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5725.
https://doi.org/10.1158/1538-7445.AM2023-5725
Published: 04 April 2023
View article titled, Abstract 5725: The USP1 inhibitor I-138 kills BRCA1-deficient tumor cells and overcomes PARP inhibitor resistance
Journal Articles

Abstract 6210: Combination of M1774 and niraparib can overcome ATR and PARP inhibitor resistance in BRCA1 mutated ovarian cancer models

Jie Hao, Arindam Bose, Golbahar Sadatrezaei, David B. Martignetti, Yuqing Jiao, Alexandre André B. da Costa, Jean-Bernard Lazaro, Bose Kochupurakkal, Huy Nguyen, Kalindi Parmar, Alan D. D’Andrea, Geoffrey I. Shapiro
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6210.
https://doi.org/10.1158/1538-7445.AM2023-6210
Published: 04 April 2023
View article titled, Abstract 6210: Combination of M1774 and niraparib can overcome ATR and PARP inhibitor resistance in BRCA1 mutated ovarian cancer models
Journal Articles

Abstract 6208: Targeting DNA polymerase theta and ATM leads to synergistic killing of mantle cell lymphoma cells

Jithma Prasad Abeykoon, Shuhei Asada, Kalindi Parmar, Xiaosheng Wu, Thomas Witzig, Geoffrey Shapiro, Alan D. D'Andrea
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6208.
https://doi.org/10.1158/1538-7445.AM2023-6208
Published: 04 April 2023
View article titled, Abstract 6208: Targeting DNA polymerase theta and ATM leads to synergistic killing of mantle cell lymphoma cells
Journal Articles

Abstract 6190: Polymerase theta inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in BRCA-deficient cancers

Jeffrey Patterson-Fortin, Heta Jadhav, Constantia Pantelidou, Tin Phan, Carter Grochala, Anita K. Mehta, Jennifer L. Guerriero, Gerburg M. Wulf, Brian M. Wolpin, Ben Z. Stanger, Andrew J. Aguirre, James M. Cleary, Alan D. D'Andrea, Geoffrey I. Shapiro
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6190.
https://doi.org/10.1158/1538-7445.AM2023-6190
Published: 04 April 2023
View article titled, Abstract 6190: Polymerase theta inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in BRCA-deficient cancers
Journal Articles

Abstract IA002: Inherited DNA repair defects and premature aging

Alan D. D'Andrea
Journal: Cancer Research
Cancer Res (2023) 83 (2_Supplement_1): IA002.
https://doi.org/10.1158/1538-7445.AGCA22-IA002
Published: 15 January 2023
View article titled, Abstract IA002: Inherited DNA repair defects and premature aging
Journal Articles

Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers

Jeffrey Patterson-Fortin, Arindam Bose, Wei-Chih Tsai, Carter Grochala, Huy Nguyen, Jia Zhou, Kalindi Parmar, Jean-Bernard Lazaro, Joyce Liu, Kelsey McQueen, Geoffrey I. Shapiro, David Kozono, Alan D. D'Andrea
Journal: Cancer Research
Cancer Res (2022) 82 (20): 3815–3829.
https://doi.org/10.1158/0008-5472.CAN-22-1124
Published: 17 October 2022
View article titled, Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in <em>TP53</em>-Mutant Cancers
Open the PDF for Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in <em>TP53</em>-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract 796: Dual inhibition of NHEJ and MMEJ induces synthetic lethality in TP53 mutant cancers

Jeffrey Patterson-Fortin, Arindam Bose, Wei-Chih Tsai, Carter Grochala, Huy Nguyen, Jia Zhou, Kalindi Parmar, Jean-Bernard Lazaro, Joyce Liu, Kelsey McQueen, Geoffrey I. Shapiro, David Kozono, Alan D. D'Andrea
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 796.
https://doi.org/10.1158/1538-7445.AM2022-796
Published: 15 June 2022
View article titled, Abstract 796: Dual inhibition of NHEJ and MMEJ induces synthetic lethality in TP53 mutant cancers
Journal Articles

Abstract 2747: Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer

Inga-Maria P. Launonen, Nuppu Lyytikäinen, Julia Casado, Ella A. Anttila, Connor A. Jacobson, Jia R. Lin, Zoltan Maliga, Sandro Santaga, Kevin M. Elias, Alan D. D'Andrea, Panagiotis A. Konstantinopoulos, Peter K. Sorger, Anniina Färkkilä
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2747.
https://doi.org/10.1158/1538-7445.AM2021-2747
Published: 01 July 2021
View article titled, Abstract 2747: Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
Journal Articles

Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells

Anniina Färkkilä, Alfredo Rodríguez, Jaana Oikkonen, Doga C. Gulhan, Huy Nguyen, Julieta Domínguez, Sandra Ramos, Caitlin E. Mills, Fernando Pérez-Villatoro, Jean-Bernard Lazaro, Jia Zhou, Connor S. Clairmont, Lisa A. Moreau, Peter J. Park, Peter K. Sorger, Sampsa Hautaniemi, Sara Frias, Alan D. D'Andrea
Journal: Cancer Research
Cancer Res (2021) 81 (10): 2774–2787.
https://doi.org/10.1158/0008-5472.CAN-20-2912
Published: 15 May 2021
View article titled, Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in <em>TP53-</em> and <em>BRCA1</em>-Deficient Cells
Open the PDF for Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in <em>TP53-</em> and <em>BRCA1</em>-Deficient Cells in another window
Includes: Supplementary data
Journal Articles

Exploiting the Microhomology-Mediated End-Joining Pathway in Cancer Therapy

Jeffrey Patterson-Fortin, Alan D. D'Andrea
Journal: Cancer Research
Cancer Res (2020) 80 (21): 4593–4600.
https://doi.org/10.1158/0008-5472.CAN-20-1672
Published: 03 November 2020
View article titled, Exploiting the Microhomology-Mediated End-Joining Pathway in Cancer Therapy
Open the PDF for Exploiting the Microhomology-Mediated End-Joining Pathway in Cancer Therapy in another window
Journal Articles

Abstract 4487: Association of the tumor-immune microenvironment with response to niraparib and pembrolizumab in relapsed, platinum-resistant ovarian cancer

Anniina Farkkila, Jia R. Lin, Julia Casado, Huy Nguyen, Yinghui Zhou, Julie R. Graham, Bruce J. Dezube, Steven Waggoner, Pamela Munster, Gini F. Fleming, Sandro Santagata, Ursula A. Matulonis, Peter K. Sorger, Elizabeth M. Swisher, Alan D. D’Andrea, Panagiotis Konstantinopoulos
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4487.
https://doi.org/10.1158/1538-7445.AM2019-4487
Published: 01 July 2019
View article titled, Abstract 4487: Association of the tumor-immune microenvironment with response to niraparib and pembrolizumab in relapsed, platinum-resistant ovarian cancer
Journal Articles

Abstract 368A: Functional assessment of DNA damage repair defects and the anti-tumor immune response in high grade serous ovarian cancers using patient-derived organoids

Sarah J. Hill, Patrick Lizotte, Neil S. Horowitz, Michael G. Muto, Michael J. Worley, Colleen M. Feltmate, Bose Kochupurakkal, Khanh T. Do, Panagiotis Konstantinopoulos, Marisa R. Nucci, Joyce F. Liu, Ursula A. Matulonis, Geoffrey I. Shapiro, Ross S. Berkowitz, Christopher P. Crum, Alan D. D'Andrea
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 368A.
https://doi.org/10.1158/1538-7445.AM2019-368A
Published: 01 July 2019
View article titled, Abstract 368A: Functional assessment of DNA damage repair defects and the anti-tumor immune response in high grade serous ovarian cancers using patient-derived organoids
Journal Articles

Abstract CT232: Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors

Khanh T. Do, Sarah J. Hill, Bose Kochupurakkal, Jeffrey G. Supko, Courtney Gannon, Adrienne Anderson, Alona Muzikansky, Andrew Wolanski, Jennifer Hedglin, Kalindi Parmar, Jean-Bernard Lazaro, Joyce Liu, Susana Campos, Ursula A. Matulonis, Alan D. D'Andrea, Geoffrey I. Shapiro
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT232.
https://doi.org/10.1158/1538-7445.AM2019-CT232
Published: 01 July 2019
View article titled, Abstract CT232: Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors
Journal Articles

Abstract IA17: PARP inhibitor resistance in prostate cancer

Alan D. D’Andrea
Journal: Cancer Research
Cancer Res (2018) 78 (16_Supplement): IA17.
https://doi.org/10.1158/1538-7445.PRCA2017-IA17
Published: 14 August 2018
View article titled, Abstract IA17: PARP inhibitor resistance in prostate cancer
Journal Articles

Abstract 139: DNA damage and immunoprofiling with highly multiplexed tissue immunofluorescence (t-CycIF) in high-grade serous ovarian cancer

Anniina Farkkila, Sameer S. Chopra, Jia-Ren Lin, Zoltan Maliga, Bose Koruchupakkal, Kyle C. Strickland, Brooke E. Howitt, Sandro Santagata, Ursula A. Matulonis, Kevin Elias, Elizabeth M. Swisher, Panagiotis A. Konstantinopoulos, Peter Sorger, Alan D. D'Andrea
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 139.
https://doi.org/10.1158/1538-7445.AM2018-139
Published: 01 July 2018
View article titled, Abstract 139: DNA damage and immunoprofiling with highly multiplexed tissue immunofluorescence (t-CycIF) in high-grade serous ovarian cancer
Journal Articles

Abstract 1620: ATR inhibition for the treatment of ATM-deficient gastric cancer

Mu-Yan Cai, Hunter D. Reavis, Jie-Wei Chen, Chirag Ganesa, Bose Kochupurakkal, Geoffrey I. Shapiro, Alan D. D'Andrea
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1620.
https://doi.org/10.1158/1538-7445.AM2018-1620
Published: 01 July 2018
View article titled, Abstract 1620: ATR inhibition for the treatment of ATM-deficient gastric cancer
Journal Articles

Abstract IA12: Targeting DNA repair in cancer therapy

Alan D. D'Andrea
Journal: Cancer Research
Cancer Res (2017) 77 (22_Supplement): IA12.
https://doi.org/10.1158/1538-7445.NEWFRONT17-IA12
Published: 14 November 2017
View article titled, Abstract IA12: Targeting DNA repair in cancer therapy
Journal Articles

Abstract 4189: Homologous recombination pathway-based biomarkers for treatment of non-small cell lung cancer with PARP inhibitors

Peter V. Deraska, Hunter D. Reavis, Shelby Labe, Alan D. D'Andrea, David Kozono
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4189.
https://doi.org/10.1158/1538-7445.AM2017-4189
Published: 01 July 2017
View article titled, Abstract 4189: Homologous recombination pathway-based biomarkers for treatment of non-small cell lung cancer with PARP inhibitors
Journal Articles

Abstract CT047: Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors

Geoffrey I. Shapiro, Khanh T. Do, Sara M. Tolaney, John F. Hilton, James M. Cleary, Andrew Wolanski, Brian Beardslee, Faith Hassinger, Ketki Bhushan, Dongpo Cai, Elizabeth Downey, Solida Pruitt-Thompson, Suzanne M. Barry, Bose Kochupurakkal, Joseph Geradts, Christine Unitt, Alan D. D'Andrea, Alona Muzikansky, Richard Piekarz, L. Austin Doyle, Jeffrey Supko
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT047.
https://doi.org/10.1158/1538-7445.AM2017-CT047
Published: 01 July 2017
View article titled, Abstract CT047: Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors
Journal Articles

Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort

Panagiotis A. Konstantinopoulos, William T. Barry, Michael Birrer, Shannon N. Westin, Sarah Farooq, Karen Cadoo, Christin Whalen, Weixiu Luo, Hui Liu, Carol Aghajanian, David B. Solit, Gordon B. Mills, Barry S. Taylor, Helen Won, Michael F. Berger, Sangeetha Palakurthi, Joyce F. Liu, Lew Cantley, Scott H. Kaufmann, Elizabeth M. Swisher, Alan D. D'Andrea, Eric Winer, Gerburg M. Wulf, Ursula A. Matulonis
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT008.
https://doi.org/10.1158/1538-7445.AM2017-CT008
Published: 01 July 2017
View article titled, Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort